The Sickle Cell Disease Treatment Market offers significant opportunities with advancements in gene editing, stem cell therapies, and precision medicine driving innovation. Increased awareness and ...
The Alpha-1 Antitrypsin Deficiency Disease market offers opportunities in developing targeted therapies due to an increasing diagnosed patient population, advances in genetic testing, and innovative ...
On Monday, 10 November 2025, the healthcare world was abuzz as two pharmaceutical giants, Pfizer and Novo Nordisk, fiercely ...
Metsera, the US biotech with a pipeline of next-generation metabolic hormone weight loss drugs, has agreed a sale to Pfizer ...
By Mariam Sunny (Reuters) -Shares of Metsera fell over 15% in early trading on Monday, after the weight-loss drug developer ...
Wall Street indexes rise as signs of progress emerge in Washington to end the government shutdown and stabilize the economy.
Pharmaceutical giant Pfizer has finally acquired development-stage obesity drugmaker Metsera Inc., in an intense bidding war against the Danish drugmaker Novo Nordisk for over $10 billion.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback